pills.jpgIPNews® – The Federal Circuit on Friday affirmed the validity of Eli Lilly & Co.’s patent for its chemotherapy treatment Alimta, rejecting a challenge from generic drug makers Teva Parenteral Medicines Inc., Barr Laboratories Inc. and APP Pharmaceuticals Inc.

The three companies were seeking regulatory approval to market generic versions of Alimta, and contended that

dna-strand.jpgSan Diego – Human Genome Sciences recently received a favorable ruling in a patent dispute with Eli Lilly concerning the validity of a patent for a gene sequence for use in developing treatments for people with immune diseases.

Eli Lilly originally contested the European patent owned by Human Genome on the grounds that the patent was too vague